Faldaprevir demonstrates good early response in genotype 1 HIV/HCV co-infection

The HCV protease inhibitor faldaprevir added to pegylated interferon and ribavirin increased the likelihood that HIV/HCV co-infected people would achieve a sustained virological response at four weeks after completing treatment, according to a report at the 14th European AIDS Conference last week in Brussels.

http://www.aidsmap.com/page/2782646/